{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:27Z","timestamp":1785484707518,"version":"3.56.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100566","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:18:03Z","timestamp":1768436283000},"page":"100566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Vincent T.","family":"Taillefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-0944","authenticated-orcid":false,"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2026.100566_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1059914","article-title":"The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends","volume":"13","author":"Chu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lrr.2026.100566_bib0002","article-title":"Surveillance, epidemiology and end results (SEER) programs","year":"2024","journal-title":"Can. Stat Facts"},{"key":"10.1016\/j.lrr.2026.100566_bib0003","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program."},{"issue":"9","key":"10.1016\/j.lrr.2026.100566_bib0004","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol. Blood Marrow TransPlant"},{"issue":"3","key":"10.1016\/j.lrr.2026.100566_bib0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.hoc.2016.01.004","article-title":"Autologous stem cell mobilization and collection","volume":"30","author":"Hsu","year":"2016","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"7","key":"10.1016\/j.lrr.2026.100566_bib0006","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol. Blood Marrow TransPlant"},{"issue":"9","key":"10.1016\/j.lrr.2026.100566_bib0007","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"Gertz","year":"2010","journal-title":"Bone Marrow TransPlant"},{"issue":"31","key":"10.1016\/j.lrr.2026.100566_bib0008","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2026.100566_bib0009","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3906\/sag-2008-114","article-title":"Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience","volume":"51","author":"Batgi","year":"2021","journal-title":"Turk. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.lrr.2026.100566_bib0010","doi-asserted-by":"crossref","first-page":"e885","DOI":"10.1016\/j.clml.2022.06.015","article-title":"Gemcitabine, Cisplatin, and Dexamethasone as a salvage and mobilization chemotherapy before autologous stem cell transplantation is effective and safe outpatient regimen in relapsed and refractory Hodgkin Lymphoma patients","volume":"22","author":"Gokmen","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.lrr.2026.100566_bib0011","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1080\/10428194.2020.1762882","article-title":"Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"61","author":"Tang","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.lrr.2026.100566_bib0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bbmt.2016.03.030","article-title":"Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with diffuse large B cell lymphoma","volume":"22","author":"Lisenko","year":"2016","journal-title":"Biol. Blood Marrow TransPlant"},{"issue":"2","key":"10.1016\/j.lrr.2026.100566_bib0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00277-015-2557-y","article-title":"Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group","volume":"95","author":"Giebel","year":"2016","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.lrr.2026.100566_bib0014","first-page":"696","article-title":"Revisiting the utility of granulocyte colony-stimulating factor post-autologous hematopoietic stem cell transplantation for outpatient-based transplantations","volume":"29","author":"Portuguese","year":"2023","journal-title":"TransPlant Cell Ther."},{"issue":"6","key":"10.1016\/j.lrr.2026.100566_bib0015","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1600-0609.2006.00741.x","article-title":"Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma\u2013results of a prospective multicentre controlled trial","volume":"77","author":"Faber","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.lrr.2026.100566_bib0016","first-page":"2083","article-title":"Effect of mannitol on acute kidney injury induced by cisplatin","volume":"29","author":"Begin","year":"2021","journal-title":"Support. Care Cancer"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:12:08Z","timestamp":1785481928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"alternative-id":["S2213048926000063"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100566","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100566"}}